Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.62 |
| ▸ | CDC7 | O00311 | 10/20 | 0.61 |
| ▸ | DBF4 | Q9UBU7 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049072 | 0.91 | TRPM8 (0.64) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL28245821 | 0.90 | CDC7 (0.57) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049127 | 0.88 | TRPM8 (0.62) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049103 | 0.85 | RAB9A (0.62) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049068 | 0.82 | TRPM8 (0.67) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL892889 | 0.81 | CDC7 (0.77) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL28245823 | 0.81 | CDC7 (0.57) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049178 | 0.80 | TRPM8 (0.61) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049292 | 0.80 | TRPM8 (0.64) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL15049004 | 0.77 | TRPM8 (1.00) | TRPM8CDC7DBF4MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | claimed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | claimed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | claimed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | claimed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | claimed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | claimed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | claimed |
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885CDC7 2527/4885DBF4 3635/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | TRPM8 1/4885CDC7 3237/4885DBF4 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.